A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)
Covid19
Enrolment: 55 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Covid19
Enrolment: 55 · Results not recorded
Ischemic Cardiomyopathy · Chronic Ischemic Cardiomyopathy
Enrolment: 0 · Results not recorded
Pulmonary Arterial Hypertension (PAH)
Enrolment: 26 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Myocardial infarction by 60-minute coronary occlusion followed by reperfusion
Cardiac mesenchymal cell administration preferentially recruited innate immune cells such as monocytes/macrophages and neutrophils, and paracrine signalling enhanced innate immune cell chemoattraction, survival and phagocytosis while diminishing pro-inflammatory activation.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.